A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa

Journal of the National Cancer Institute

Volumn 90, Issue 11, 1998, Pages 850-858

  Hasford, Joerg ^a   Pfirrmann, Markus ^a   Hehlmann, Rüdiger ^b   Allan, Norman C ^c   Baccarani, Michele ^d   Kluin Nelemans, Johanna C ^e   Alimena, Guiliana ^f   Steegmann, Juan Luis ^g   Ansari, Hassan ^h  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF UDINE   (Italy)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h Biometric Center for Therapeutic Studies   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GAMMA INTERFERON; HYDROXYUREA; RECOMBINANT ALPHA INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROGNOSIS; SCORING SYSTEM;

EID: 0032478962     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.11.850     Document Type: Article

References (34)

1. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
2. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86: 906-16.
3. Hasford J, Ansari H, Pfirrmann M, Hehlmann R. Analysis and validation of prognostic factors for CML. German CML Study Group. Bone Marrow Transplant 1996;17(Suppl 3):S49-S54.
4. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia. Effect on remission duration and survival: Cancer and Leukemia Group B Study 8593. Blood 1993;82: 2975-84.
5. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 1990;88: 1-8.
6. Byar DP. Identification of prognostic factors. In: Buyse ME, Staquet MJ, Sylvester RS, editors. Cancer clinical trials. Methods and practice. Oxford, England: Oxford University Press, 1984:423-43.
7. Thaler J, Gastl G, Fluckinger T, Niederuieser D, Huber H, Seewann H, et al. Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group. Semin Hematol 1993;30(Suppl 3):17-19.
8. Thaler J and Hilbe W. Comparative analysis of two consecutive phase II studies with IFN-alpha and IFN-alpha + ara-C in untreated chronic-phase CML patients. Austrian CML Study Group. Bone Marrow Transplant 1996;17(Suppl 3):S25-S28.
9. Department of Hematology, Leiden University Hospital, The Netherlands. Low-dose interferon alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia. The Benelux CML Study Group. Bone Marrow Transplant 1996;17(Suppl 3):S19-S20.
10. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alfa2b for chronic myeloloid leukemia. Blood 1998;91:2713-21.
11. Guilhot F. Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group. Semin Hematol 1993;30(Suppl 3):24-5.
12. Guilhot F, Guerci A, Fiere D, Harousseau JL, Maloisel F, Bouabdallah R, et al. The treatment of chronic myelogenous leukemia by Interferon and cytosine-arabinoside: rationale and design of the French trials. French CML Study Group. Bone Marrow Transplant 1996;17: S29-S32.
13. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. German CML Study Group. Blood 1994;84:4064-77.
14. Hehlmann R, Heimpel H, Hossfeld DK, Hasford J, Kolb HJ, Loffler H, et al. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II) The German Study Group. Bone Marrow Transplant 1996;17(Suppl 3): S21-S24.
15. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995;345:1392-7.
16. Interferon-alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 1994;330: 820-5.
17. Fernandez-Ranada JM, Lavilla E, Odriozola J, Garcia-Larana J, Lozano M, Parody R, et al. Interferon alfa 2A in the treatment of chronic myelogenous leukemia in chronic phase. Results of the Spanish Group. Leuk Lymphoma 1993;11(Suppl 1):175-9.
18. Kloke O, Niederle N, Qiu JY, Wandl U, Moritz T, Nagel-Hiemke M, et al. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 1993;83:399-403.
19. Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inveradi D, et al. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration. Blood 1988;72: 642-7.
20. Moro MJ, Gil S, Canizo C, Clemente JF, Guerras L, Fisac RM, et al. The treatment of chronic myelogenous leukemia with interferon alfa-2b plus hydroxyurea versus hydroxyurea alone. Haematologica 1991;76(Suppl 4): 117.
21. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949.
22. SAS Institute Inc. SAS/STAT Software: Changes and enhancements through Release 6.11. Cary (NC): SAS Institute, Inc., 1996.
23. Harris EK, Albert A. Survivorship analysis for clinical studies. New York: Marcel Dekker, 1991.
24. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees (CART). Belmont, CA: Wandsworth, 1984.
25. Brandmaier R, Ansari H, Dickson D. A general SAS macro for construction of classification and regression trees. In: Proceedings of the 18th annual SAS User Group International (SUGI) Conference, Cary (NC): SAS Institute, Inc., USA. 1993;1032-35.
26. Ansari H, Aydemir Ü, Dirschedl P, Hasford J, Hehlmann R. Analyse von prognostischen Faktoren bei Patienten mit chronisch-myeloischer Leukámie (CML)-Ein Vergleich von CART-Technik und Cox-Modell. In: Michaelis J, Hommel G, Wellek S, editors. Europáische Perspektiven der Medizinischen Informatik, Biometrie und Epidemiologie. Medizinische Informatik, Biometrie und Epidemiologie 76. München:MMV Medizin Verlag, 1993: 168-72.
27. Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics 1992;48:73-85.
28. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
29. Collett D. Modelling survival data in medical research. London: Chapman & Hall, 1994.
30. Sokal JE, Baccarani M, Tura S, Fiacchini M, Cervantes F, Rozman C, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 1985;66: 1352-7.
31. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223-9.
32. Hasford J, Baccarani M, Hehlmann R, Ansari H, Tura S, Zuffa E. Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trial with interferon-alpha. Blood 1996;87:5384-91.
33. Kantarjian HM, Keating MJ, Smith TL, O'Brien S, Beran M, Pierce S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995;122:254-61.
34. Hehlmann R, Heimpel H, Hasford J, and the German CML Study Group. Randomized comparison of interferon-alpha. hydroxyurea and busulfan in chronic myeloid leukemia: Response to Kantarjian and Talpaz and to Tura and Baccarani [letter]. Blood 1995;85:3000-2.